Levofloxacin plus aminoglycoside superior to ciprofloxacin after prostate biopsy
the ONA take:
This study investigated the potential benefit of oral fluoroquinolone prophylaxis in patients undergoing transrectal ultrasound-guided (TUG) prostate biopsy.
The researchers compared two prophylactic antibiotic regimens: one dose of ciprofloxacin 500 mg combined with an aminoglycoside (AG) or one dose of levofloxacin 750 mg combined with an AG.
The ciprofloxacin group involved 535 biopsies, and the levofloxacin 654 biopsies. Total infection rate was 3.18% in the ciprofloxacin group and 2.14% in the levofloxacin group.
The rate of mild infection was 0.75% in the ciprofloxacin group and 1.22% in the levofloxacin group; however, the rate of severe infection was higher in the ciprofloxacin group compared with the levofloxacin group (2.43% vs 0.92%, respectively).
Use of a single dose of fluoroquinolone augmented with an AG is optimal prophylaxis to reduce infectious complications in patients undergoing prostate biopsy.
The researchers found that 750 mg levofloxacin is more effective than 500 mg ciprofloxacin in reducing severe infections in these patients.
Use of single dose of fluoroquinoloneis optimal prophylaxis to reduce infectious complications in patients undergoing prostate biopsy.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|